All News
Adrenal Dysfunction after Steroids in PMR and GCA Patients
JAMA has published a study of PMR and GCA patients who stopped glucocorticoid (GC) therapy and noted a low (1.2%) risk of GC-induced adrenal insufficiency after planned cessation.
Read Article
ACR Frustrated with Congress Failures on Physician Fee Schedule and Research Programs
d
ACR
The American College of Rheumatology (ACR) expressed deep dissatisfaction that the recent passage of the Full-Year Continuing Appropriations and Extensions Act, failed to address payment cuts imposed in the CY25 Medicare Physician Fee Schedule (MPFS) at the beginning of
Read Article
PAFLAR Guidelines for Polyarticular Juvenile Idiopathic Arthritis
The Pediatric African League against Rheumatism (PAFLAR) initiative has published its guidelines for the diagnosis and treatment of polyarticular juvenile idiopathic arthritis (pJIA).
Ontario study of 11 641 older psoriasis pts & hospitalized serious infx in those on b/tsDMARDs. IL-12, IL-23, and IL-17 inhibitors were assoc w/ 35% lower rates of SIE, while MTX, other older systemic meds, TNFi were not incr/decr. But JAK inhibitors had signif 3 fold incr in… https://t.co/ffFdHjme65 https://t.co/DkTsadUNx2
Dr. John Cush RheumNow ( View Tweet)
Effectiveness of IL-6 Receptor Inhibitors versus Methotrexate or any Conventional Immunomodulators in Patients with Steroid Refractory Polymyalgia Rheumatica
Sponsored by Sanofi
https://t.co/z6tqpblbOZ https://t.co/FxsMMbCFdX
Dr. John Cush RheumNow ( View Tweet)
Study of 26 Enthesitis-related arthritis (ERA) pts (mean Dx age 12 yrs; 77% male; 58% B27+). These were later assessed as adults (20yrs age, <35yrs). Most were in remission/LDAS, but ~20% had synovitis or enthesitis, 73% SI Dz, 15% hip & 8% spinal damage https://t.co/FFEhyA5I6A https://t.co/hE65GNcFpY
Dr. John Cush RheumNow ( View Tweet)
Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Sponsored by Amgen
https://t.co/Grf708Dmfb https://t.co/MvaN0lzsoG
Dr. John Cush RheumNow ( View Tweet)
RF levels may offer critical insights when treating RA. Learn why from two renowned rheumatologists. Sponsored by UCB
https://t.co/yuUhmZR5bC https://t.co/Fsbu8Vztna
Dr. John Cush RheumNow ( View Tweet)
An IL-23i in PsA: Maintenance of treatment response through ~4 years in Phase 3 studies
Discover the post hoc analysis presented at the Fall 2024 Clinical Dermatology Conference in the poster hall. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/dLx76SY36R https://t.co/pzCcMQ6hin
Dr. John Cush RheumNow ( View Tweet)
Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs
A retrospective US administrative claims cohort study of Rheumatoid arthritis (RA) patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a… https://t.co/8jqJwkEbZF https://t.co/cQ9aheU5mc
Dr. John Cush RheumNow ( View Tweet)
Indigenous peoples of the Pacific, particularly those of Polynesian descent, have a high prevalence of hyperuricaemia and gout. Gout in Indigenous peoples of the Pacific is severe, associated with family history and is experienced at a relatively young age.… https://t.co/phf5RRkJzE https://t.co/q4VO34Ea5z
Dr. John Cush RheumNow ( View Tweet)
Earlier ACL reconstruction and a lower risk of knee osteoarthritis
A preclinical study by HSS investigators found that earlier ACL reconstruction led to lower immune cell activity, less inflammation and fewer joint changes associated with knee osteoarthritis compared to delayed… https://t.co/DnY5nGLah4 https://t.co/ogLTF88CVL
Dr. John Cush RheumNow ( View Tweet)
Glucocorticoid Toxicity Index
Dr. John Stone has led the effort to develop the GTI - glucocorticoid toxicity index. In this review article he acknowledges the need and benefit of steroids, but details a novel means to identify and limit the untoward effects of glucorticoids… https://t.co/xR8D4Jpjfv https://t.co/LyfHrbneTO
Dr. John Cush RheumNow ( View Tweet)
Comprehensive review of the management of knee osteoarthritis - topicals, analgesics, narcotics, intraarticular, metabolic, nutraceuticals, TENS, acupuncture and biologics. https://t.co/SEyG4IQ0bh https://t.co/f6UY4hEl18
Dr. John Cush RheumNow ( View Tweet)
Single Center study of 112 RA pts from Morocco used machine learning (ML) logistic regression model & identified #Depression in 48% (HADS score >8) w/ 76.5% accuracy, 72.2% precision, 81.2% recall, and an area under the receiver operating characteristic curve (ROC AUC) of… https://t.co/LBvdVEzDGJ https://t.co/bYLqsFagbR
Dr. John Cush RheumNow ( View Tweet)
2024 Rheumatology Year in Review
2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.
https://t.co/XuEG8Hrc9e https://t.co/ja5OoZXdWo
Dr. John Cush RheumNow ( View Tweet)
Cardiovascular and Fracture Risk with Denosumab Versus Bisphosphonates in Dialysis Patients
Annals of Internal Medicine has published a Japanese administrative claims database study showing that, compared with oral bisphosphonates (BIS), denosumab (DEN) lowered fracture risk… https://t.co/kNqGNTrsAF https://t.co/xgCeaMDT1N
Dr. John Cush RheumNow ( View Tweet)
Increased Mortality In Arthritis Patients with COPD
A new study published in the January 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal, finds that people with chronic obstructive pulmonary disease… https://t.co/6WCtfcrSaq https://t.co/ydVtBxqy37
Dr. John Cush RheumNow ( View Tweet)
Congress Passes Fiscal Year 2025 Funding for Lupus Programs, including
- $10 million Natl Lupus Patient Registry at CDC
- $2 million Natl Lupus Training, Outreach, CTE Program
- $47.08 billion for the National Institutes of Health SLE prgs https://t.co/BCs3lGdrXK https://t.co/58PkKG9ay6
Dr. John Cush RheumNow ( View Tweet)
Stelara Biosimilar Steqeyma Launches at 85% Discount https://t.co/2ZR7LMq1JT https://t.co/coHj1jh8JB
Dr. John Cush RheumNow ( View Tweet)